Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

65 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
First-line venetoclax combinations versus chemoimmunotherapy in fit patients with chronic lymphocytic leukaemia (GAIA/CLL13): 4-year follow-up from a multicentre, open-label, randomised, phase 3 trial.
Fürstenau M, Kater AP, Robrecht S, von Tresckow J, Zhang C, Gregor M, Thornton P, Staber PB, Tadmor T, Lindström V, Juliusson G, Janssens A, Levin MD, da Cunha-Bang C, Schneider C, Goldschmidt N, Vandenberghe E, Rossi D, Benz R, Nösslinger T, Heintel D, Poulsen CB, Christiansen I, Frederiksen H, Enggaard L, Posthuma EFM, Issa DE, Visser HPJ, Bellido M, Kutsch N, Dürig J, Stehle A, Vöhringer M, Böttcher S, Schulte C, Simon F, Fink AM, Fischer K, Holmes EE, Kreuzer KA, Ritgen M, Brüggemann M, Tausch E, Stilgenbauer S, Hallek M, Niemann CU, Eichhorst B. Fürstenau M, et al. Among authors: robrecht s. Lancet Oncol. 2024 Jun;25(6):744-759. doi: 10.1016/S1470-2045(24)00196-7. Lancet Oncol. 2024. PMID: 38821083 Free article. Clinical Trial.
Infections in patients with chronic lymphocytic leukemia treated with time limited targeted drug combinations.
Langerbeins P, Giza A, Robrecht S, Cramer P, von Tresckow J, Al-Sawaf O, Fink AM, Fürstenau M, Kater A, van der Spek E, Niemann CU, da Cunha-Bang C, Tausch E, Schneider C, Stilgenbauer S, Fischer K, Hallek M, Eichhorst B. Langerbeins P, et al. Among authors: robrecht s. Am J Hematol. 2024 May 17. doi: 10.1002/ajh.27367. Online ahead of print. Am J Hematol. 2024. PMID: 38757754 No abstract available.
Fludarabine, cyclophosphamide, and rituximab as first-line treatment in patients with chronic lymphocytic leukemia: A long-term analysis of the German CLL Study Group (GCLLSG) registry.
Kutsch N, Giza A, Robrecht S, Stumpf J, Federhen A, Stoltefuß A, Vehling-Kaiser U, Koenigsmann M, Tausch E, Schneider C, Stilgenbauer S, Illmer T, Schlag R, Dörfel S, Gaska T, Kiehl M, Müller-Hagen S, Moorahrend E, Linde H, Schlenska-Lange A, von Tresckow J, Fischer K, Eichhorst B, Hallek M, Fink AM. Kutsch N, et al. Among authors: robrecht s. Eur J Haematol. 2024 May 1. doi: 10.1111/ejh.14220. Online ahead of print. Eur J Haematol. 2024. PMID: 38693677
Reassessing the Chronic Lymphocytic Leukemia International Prognostic Index in the era of targeted therapies.
Langerbeins P, Giza A, Robrecht S, Cramer P, von Tresckow J, Al-Sawaf O, Fink AM, Fürstenau M, Kutsch N, Simon F, Goede V, Hoechstetter MA, Niemann CU, da Cunha-Bang C, Kater AP, Dubois J, Gregor M, Staber PB, Tausch E, Schneider C, Stilgenbauer S, Eichhorst B, Fischer K, Hallek MJ. Langerbeins P, et al. Among authors: robrecht s. Blood. 2024 Apr 15:blood.2023022564. doi: 10.1182/blood.2023022564. Online ahead of print. Blood. 2024. PMID: 38620092
Acalabrutinib, venetoclax and obinutuzumab in relapsed CLL: Final efficacy and ctDNA analysis of the CLL2-BAAG trial.
Fürstenau M, Giza A, Weiss J, Kleinert F, Robrecht S, Franzen F, Stumpf J, Langerbeins P, Al-Sawaf O, Simon F, Fink AM, Schneider C, Tausch E, Schetelig J, Dreger P, Böttcher S, Fischer K, Kreuzer KA, Ritgen M, Schilhabel A, Brüggemann M, Stilgenbauer S, Eichhorst B, Hallek M, Cramer P. Fürstenau M, et al. Among authors: robrecht s. Blood. 2024 Apr 15:blood.2023022730. doi: 10.1182/blood.2023022730. Online ahead of print. Blood. 2024. PMID: 38620072
Bendamustine, followed by obinutuzumab and idelalisib in chronic lymphocytic leukemia (CLL2-BCG): Final analysis of a multicenter, open-label phase-II-trial.
Cramer P, von Tresckow J, Fink AM, Robrecht S, Giza A, Tausch E, Müller L, Knauf W, Zingerle M, Al-Sawaf O, Langerbeins P, Fischer K, Kreuzer KA, Kneba M, Wendtner CM, Stilgenbauer S, Eichhorst B, Hallek M. Cramer P, et al. Among authors: robrecht s. Am J Hematol. 2024 Jun;99(6):1192-1195. doi: 10.1002/ajh.27304. Epub 2024 Apr 5. Am J Hematol. 2024. PMID: 38578022 Clinical Trial. No abstract available.
Hybrid immunity to SARS-CoV-2 in patients with chronic lymphocytic leukemia.
Mellinghoff SC, Robrecht S, Sprute R, Mayer L, Weskamm LM, Dahlke C, Gruell H, Teipel F, Schlößer HA, Siepmann K, Thelen M, Fink AM, Fischer K, Klein F, Addo MM, Kolovou A, Cornely OA, Eichhorst B, Hallek M, Langerbeins P. Mellinghoff SC, et al. Among authors: robrecht s. Eur J Haematol. 2024 May;112(5):788-793. doi: 10.1111/ejh.14170. Epub 2024 Feb 4. Eur J Haematol. 2024. PMID: 38311570
Tislelizumab plus zanubrutinib for Richter transformation: the phase 2 RT1 trial.
Al-Sawaf O, Ligtvoet R, Robrecht S, Stumpf J, Fink AM, Tausch E, Schneider C, Boettcher S, Mikusko M, Ritgen M, Schetelig J, von Tresckow J, Vehling-Kaiser U, Gaska T, Wendtner CM, Chapuy B, Fischer K, Kreuzer KA, Stilgenbauer S, Staber P, Niemann C, Hallek M, Eichhorst B. Al-Sawaf O, et al. Among authors: robrecht s. Nat Med. 2024 Jan;30(1):240-248. doi: 10.1038/s41591-023-02722-9. Epub 2023 Dec 9. Nat Med. 2024. PMID: 38071379 Free PMC article. Clinical Trial.
Author Correction: Transcriptomic profiles and 5-year results from the randomized CLL14 study of venetoclax plus obinutuzumab versus chlorambucil plus obinutuzumab in chronic lymphocytic leukemia.
Al-Sawaf O, Zhang C, Jin HY, Robrecht S, Choi Y, Balasubramanian S, Kotak A, Chang YM, Fink AM, Tausch E, Schneider C, Ritgen M, Kreuzer KA, Chyla B, Paulson JN, Pallasch CP, Frenzel LP, Peifer M, Eichhorst B, Stilgenbauer S, Jiang Y, Hallek M, Fischer K. Al-Sawaf O, et al. Among authors: robrecht s. Nat Commun. 2023 Oct 23;14(1):6724. doi: 10.1038/s41467-023-42562-2. Nat Commun. 2023. PMID: 37872229 Free PMC article. No abstract available.
Final analysis of the CLL2-GIVe trial: obinutuzumab, ibrutinib, and venetoclax for untreated CLL with del(17p)/TP53mut.
Huber H, Tausch E, Schneider C, Edenhofer S, von Tresckow J, Robrecht S, Giza A, Zhang C, Fürstenau M, Dreger P, Ritgen M, Illmer T, Illert AL, Dürig J, Böttcher S, Niemann CU, Kneba M, Al-Sawaf O, Kreuzer KA, Fink AM, Fischer K, Döhner H, Hallek M, Eichhorst B, Stilgenbauer S. Huber H, et al. Among authors: robrecht s. Blood. 2023 Sep 14;142(11):961-972. doi: 10.1182/blood.2023020013. Blood. 2023. PMID: 37363867
65 results